Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486614 | 0.88 | MEN1 (0.57) | HDAC1MAOAPTGS2NOTUMALDH1A1 | |
| SCHEMBL4665845 | 0.86 | PDE3B (0.55) | HDAC1MAOALTA4HTHRATHRB | |
| SCHEMBL2942026 | 0.83 | PTPN7 (0.58) | HDAC1MAOALTA4HKDM4EHSD17B10 | |
| SCHEMBL29843519 | 0.83 | PTPN7 (0.58) | HDAC1MAOALTA4HKDM4EHSD17B10 | |
| SCHEMBL8983204 | 0.79 | MAOA (0.60) | HDAC1MAOALTA4HMAOBTHRA | |
| SCHEMBL27505830 | 0.77 | MAOA (0.57) | HDAC1MAOAMAOBTHRATHRB | |
| SCHEMBL2013244 | 0.77 | MAOA (0.61) | HDAC1MAOAPTGS2MAOBTHRA | |
| SCHEMBL11259267 | 0.76 | LTA4H (0.52) | HDAC1MAOALTA4HMAOBKDR | |
| SCHEMBL30360394 | 0.76 | PTPN7 (0.67) | ALDH1A1MEN1KMT2A | |
| SCHEMBL2474817 | 0.76 | PTPN7 (0.67) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| EP-2661433-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | Novartis AG (CH) | 2013-11-13 | — | — | EP | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2012093101-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2012-07-12 | — | — | WO | disclosed |
| US-20080234349-A1 | PPAR active compounds | PLEXXIKON INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080234349-A1 | PPAR active compounds | PLEXXIKON INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080234349-A1 | PPAR active compounds | PLEXXIKON INC. | 2008-09-25 | — | — | US | disclosed |
| EP-1931658-A2 | 1 , 4 AND 1 , 5-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007030574-A2 | 1 , 4 AND 1 , 5-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030574-A2 | 1 , 4 AND 1 , 5-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20050203151-A1 | Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions | KALYPSYS, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| WO-2005060958-A1 | (5- (2-PHENYL)-THIAZOL-5-YLMETHOXY)-INDOL-1-YL) -ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE HUMAN PPAR-DELTA RECEPTOR FOR THE TREATMENT OF METABOLIC DISORDERS SUCH AS TYPE 2 DIABETES | KALYPSYS, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203151-A1 | Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions | PPARG, PPARD, PPARA | HDAC1 381/4885MAOA 3295/4885LTA4H 747/4885 |
| US-20080234349-A1 | PPAR active compounds | PPARG, PPARA, PPARD | HDAC1 227/4885MAOA 4357/4885LTA4H 1796/4885 |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | HDAC1 3836/4885MAOA 457/4885LTA4H 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.